(Q38361567)

English

AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats (English)

1 reference

Europe PubMed Central

2 September 2017

0 references

insulin resistance

1 reference

based on heuristic

inferred from title

author name string

Bengt Ljung

1

1 reference

Europe PubMed Central

2 September 2017

Krister Bamberg

2

1 reference

Europe PubMed Central

2 September 2017

Björn Dahllöf

3

1 reference

Europe PubMed Central

2 September 2017

Ann Kjellstedt

4

1 reference

Europe PubMed Central

2 September 2017

Nicholas D Oakes

5

1 reference

Europe PubMed Central

2 September 2017

Jörgen Ostling

6

1 reference

Europe PubMed Central

2 September 2017

Lennart Svensson

7

1 reference

Europe PubMed Central

2 September 2017

Germán Camejo

8

1 reference

Europe PubMed Central

2 September 2017

publication date

1 November 2002

1 reference

Europe PubMed Central

2 September 2017

Journal of Lipid Research

1 reference

Europe PubMed Central

2 September 2017

43

1 reference

Europe PubMed Central

2 September 2017

1855-1863

1 reference

Europe PubMed Central

2 September 2017

11

1 reference

Europe PubMed Central

2 September 2017

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Global and societal implications of the diabetes epidemic

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Understanding coronary heart disease as a consequence of defective regulation of apolipoprotein B metabolism

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

New drug targets for type 2 diabetes and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

PPARgamma, the ultimate thrifty gene

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Peroxisome proliferator-activated receptor gamma and metabolic disease.

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501.

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

The PPARs: from orphan receptors to drug discovery

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Peroxisome proliterator-activated receptors, orphans with ligands and functions

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical mode

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Diseases of liporegulation: new perspective on obesity and related disorders

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

The cytochrome P450 4 (CYP4) family

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M200127-JLR200

21 January 2018

Identifiers

10.1194/JLR.M200127-JLR200

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38361567&oldid=1755793907"